This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Mika Kamata-Sakurai, Ph.D.
Senior Director, Translational Research Division at Chugai Pharmaceutical Co., Ltd.


Mika Kamata-Sakurai, Ph.D. is a senior director at Chugai Pharmaceutical Co., Ltd., in Japan. She has more than 10 years of experience in the pharmaceutical industry and has led multiple projects in oncology. During her career, Dr. Kamata-Sakurai has held positions in both academia and industry, focusing on the development, application, and testing of cancer vaccines, therapeutic antibodies, protein libraries, protein evolution technologies, engineered antibodies, and novel biologics. She received her Ph.D. from the University of Tokyo for her thesis on cancer immunotherapy. She is skilled in genetic engineering, molecular biology, biochemistry, and pharmacology, especially as they relate to oncology.

Agenda Sessions

  • Inducible Activation of Antibodies to Enhance Therapeutic Index

  • Novel Tumor Selective anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor Microenvironment

    On Demand